ACE and Hyperkalemia: Additionally, combination therapy with ACE inhibitors and AT1 receptor blockers in patients with cardiovascular complications is linked to an increased risk of adverse renal outcomes with higher rates of hyperkalemia, hypotension and renal dysfunction and no observed benefit with respect to overall mortality [33,34,35,36].